Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin.

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

Moderna stock has been under pressure amid declining sales of its COVID-19 vaccine. The company projects ... Notably, the company maintains a robust balance sheet to support these objectives ...

Dylan Lewis: We're talking three stocks down bad. Motley Fool Money starts down. I'm Dylan Lewis, I'm joined over the airwaves by Motley Fool analyst David Meier. David, thanks for joining me today.

Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...

It feels fantastic,” said Blau, who thanked her lab members and colleagues for their support and dedication. “This ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

The US Department of Health and Human Services will award $590 million to Moderna to continue developing a vaccine to protect ...

Chairman Larry Ellison highlighted the AI's potential in the development of mRNA-based cancer vaccines. Read more here.

Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.

There have been 67 confirmed human bird flu cases in the U.S. since April 2024. Moderna has been awarded approximately $590 million from the federal government to help speed up the development of ...